Sang Hun Song, Jaewon Lee, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong, Tae-Hwan Kim, Se Young Choi, Jong Kil Nam, Ja Yoon Ku, Kwan Joong Joo, Won Sik Jang, Young Eun Yoon, Seok Joong Yun, Sung-Hoo Hong, Jong Jin Oh
Cancer Res Treat. 2023;55(4):1337-1345. Published online April 17, 2023
Purpose Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses.
Materials and Methods Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted.
Results UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients.
Conclusion Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.
Citations
Citations to this article as recorded by
Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies Akshay Mathavan, Akash Mathavan, Rodrigo Murillo-Alvarez, Kriti Gera, Urszula Krekora, Aaron J. Winer, Mohit Mathavan, Ellery Altshuler, Brian Hemendra Ramnaraign Clinical Genitourinary Cancer.2024; 22(1): 67. CrossRef
Robotic‐assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes Caio Vinícius Suartz, Lucas Motta Martinez, Pedro Henrique Brito, Carlos Victori Neto, Maurício Dener Cordeiro, Luiz Antonio Assan Botelho, Fábio Pescarmona Gallucci, José Maurício Mota, William Carlos Nahas, Leopoldo Alves Ribeiro‐Filho BJUI Compass.2024; 5(3): 327. CrossRef
Jaewon Lee, Jin Lim, Jong Seo Park, Miso Kim, Tae-Yong Kim, Tae Min Kim, Kyung-Hun Lee, Bhumsuk Keam, Sae-Won Han, Je-Ho Mun, Kwang Hyun Cho, Seong Jin Jo
Cancer Res Treat. 2018;50(4):1186-1193. Published online December 14, 2017
Purpose
Patients treated with anticancer agents often experience a variety of treatment-related skin problems, which can impair their quality of life.
Materials and Methods
In this cross-sectional study, Dermatology Life Quality Index (DLQI) and clinical information were evaluated in patients under active anticancer treatment using a questionnaire survey and their medical records review.
Results
Of 375 evaluated subjects with anticancer therapy, 136 (36.27%) and 114 (30.40%) were treated for breast cancer and colorectal cancer, respectively. We found that women, breast cancer, targeted agent use, and longer duration of anticancer therapy were associated with higher dermatology-specific quality of life distraction. In addition, itching, dry skin, easy bruising, pigmentation, papulopustules on face, periungual inflammation, nail changes, and palmoplantar lesions were associated with significantly higher DLQI scores. Periungual inflammation and palmoplantar lesions scored the highest DLQI.
Conclusion
We believe our findings can be helpful to clinicians in counseling and managing the patients undergoing anticancer therapy.
Citations
Citations to this article as recorded by
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature Annika Belzer, Jolanta J. Pach, Kailyn Valido, Jonathan S. Leventhal American Journal of Clinical Dermatology.2024; 25(3): 435. CrossRef
Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy Maria Mannino, Pietro Sollena, Alessandro Di Stefani, Ernesto Rossi, Ettore D’Argento, Giovanni Schinzari, Giampaolo Tortora, Ketty Peris Dermatology.2024; 240(4): 523. CrossRef
A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country Areesha Abid, Humza Saeed, Uswa Iftikhar, Muhammad Khubaib Arshad, Muhammad Uzair Shahid, Tayyab Rasool, Faizan Fazal, Aman Goyal, Anum Akbar Journal of Oncology Pharmacy Practice.2024;[Epub] CrossRef
Chemotherapy induced alopecia in breast cancer patients: A monocentric prospective study Wala Ben Kridis, Olfa Boudawara, Afef Khanfir Breast Disease.2024; 43(1): 251. CrossRef
Impact of Xerosis in Patients With Cancer Receiving Epidermal Growth Factor Receptor or Mitogen-Activated Protein Kinase Inhibitors: ATIXI, A Non-Interventional, Prospective, Pilot Study Pietro Quaglino, Giuseppe Argenziano, Emi Dika, Michela Starace, Simone Amabile, Paolo Fava, Elvira Moscarella, Bianca Maria Piraccini, Alain Delarue, Olivia Dialla, Fabienne Zumaglini, Giampiero Girolomoni Dermatology Practical & Conceptual.2024; 14(4): e2024259. CrossRef
Global trends in adolescent and young adult female cancer burden, 1990-2021: insights from the Global Burden of Disease study Z. Huang, J. Wang, H. Liu, B. Wang, M. Qi, Z. Lyu, H. Liu ESMO Open.2024; 9(11): 103958. CrossRef
Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer Maham Ahmad, Sabrina Saeed, Brianna Olamiju, Andrea Silber, Jonathan Leventhal International Journal of Women’s Dermatology.2023; 9(1): e073. CrossRef
Aloe vera gel for prevention of chemotherapy-induced hyperpigmentation: Four case reports Chia-Chi Chiu, Yi-Wen Hsiao, Yu-Chuan Wen, Tsung-Yen Chang, Shih-Hsiang Chen, Tang-Her Jaing Medicine.2023; 102(25): e34037. CrossRef
Skin-related Quality of Life in Patients with Lung Cancer Taking Oral Targeted Agents: A Single-Center, Cross-Sectional Study Joo Mi Park, Jeong Hye Kim Asian Oncology Nursing.2023; 23(2): 84. CrossRef
Dermatological Side Effects of Cancer Treatment: Psychosocial Implications—A Systematic Review of the Literature Vera Almeida, Daniela Pires, Marta Silva, Maribel Teixeira, Ricardo João Teixeira, André Louro, Maria Alzira Pimenta Dinis, Maria Ferreira, Ana Teixeira Healthcare.2023; 11(19): 2621. CrossRef
The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus Brigitte Dreno, Kiarash Khosrotehrani, Giselle De Barros Silva, Julie Ryan Wolf, Delphine Kerob, Mark Trombetta, Etienne Atenguena, Pascale Dielenseger, Meng Pan, Florian Scotte, Ivan Krakowski, Mario Lacouture Supportive Care in Cancer.2023;[Epub] CrossRef
Effectiveness and Tolerability of Natural Herbal Formulations in the Prevention of Radiation-Induced Skin Toxicity in Patients Undergoing Radiotherapy Georgios Koukourakis, Georgios Pissakas, Christos G. Ganos, Gregory Sivolapenko, Dimitrios Kardamakis The International Journal of Lower Extremity Wounds.2022; 21(1): 75. CrossRef
Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes Jang‐Hee Oh, Woojune Hur, Na Li, Seong Jin Jo Experimental Dermatology.2022; 31(6): 918. CrossRef
An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study Véronique Vendrely, Ander Mayor-Ibarguren, Aline Stennevin, Ariadna Ortiz-Brugués Dermatology and Therapy.2022; 12(3): 683. CrossRef
Nail pigmentation induced by chemotherapy: an observational study of patients with early-stage breast cancer Kuikui Jiang, Simei Shi, Qiulian Lin, Peng Sun, Luan Zhang, Zhongyu Yuan, Ruoxi Hong, Yanxia Shi, Xia Liu, Jingmin Zhang, Jiajia Huang, Xiwen Bi, Wen Xia, Qianyi Lu, Qiufan Zheng, Shusen Wang, Fei Xu Holistic Integrative Oncology.2022;[Epub] CrossRef
Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new Hae‐Jin Suh, Ángeles Flórez, Víctor Sacristán, Ángeles Rodríguez Martinez, Francisca Fernández, Lucía Vilanova‐Trillo, Manuel Constenla, Manuel Pereiro International Journal of Dermatology.2021; 60(2): 208. CrossRef
The Impact of Acne, Atopic Dermatitis, Skin Toxicities and Scars on Quality of Life and the Importance of a Holistic Treatment Approach Brigitte Dreno, Jean Michel Amici, Ann Laure Demessant-Flavigny, Charlotte Wright, Charles Taieb, Seemal R Desai, Andrew Alexis Clinical, Cosmetic and Investigational Dermatology.2021; Volume 14: 623. CrossRef
Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study Hae-Jin Suh Oh, Ángeles Flórez Menéndez, Víctor Sacristán Santos, Ángeles Rodríguez Martínez, Francisca Fernández Ribeiro, Lucía Vilanova-Trillo, Manuel Constenla Figueiras, Manuel Pereiro Ferreiros Health and Quality of Life Outcomes.2021;[Epub] CrossRef
Dermatologic conditions in women receiving systemic cancer therapy Michelle N. Ferreira, Julie Y. Ramseier, Jonathan S. Leventhal International Journal of Women's Dermatology.2019; 5(5): 285. CrossRef